

Moderna announces progress in prophylactic vaccines modality with CMV Vaccine phase 2 study data now expected in third quarter 2020

This article was originally published [here](#)

The Company also announced three new vaccine development candidates, which support the Company's strategy, announced January 12, to accelerate new development candidates in its core modalities, prophylactic vaccines

The post [Moderna announces progress in prophylactic vaccines modality with CMV Vaccine phase 2 study data now expected in third quarter 2020](#) appeared first on [Pharmaceutical Business review](#).